Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

EpiThany Announces Appointment of David Poston as Chief Operating Officer

Posted on: 23 Sep 16

SEATTLE, Sept. 22, 2016 /PRNewswire/ -- EpiThany, a biotechnology company dedicated to the advancement of innovative cancer therapies, today announced the appointment of David Poston as Chief Operating Officer. Poston brings over 30 years of experience in finance and operations in the life science, engineering and technology industries.

Poston joins EpiThany from the Allen Institute, where he served as Chief Financial Officer and previously as Chief Operating Officer.  Poston joined the Allen Institute in 2011 and helped plan, lead and support teams executing over $500 million of Institute expansion initiatives including the Institute's 10-year plan for the Allen Institute for Brain Science unit, the Institute's multiple-year plans for the Allen Institute for Cell Science and The Paul G. Allen Frontiers Group, and the construction of the Institute's 270,000 square foot headquarters building.

"David's sterling credentials and deep industry experience across multiple strategic financial and operational functions will be invaluable to EpiThany as we focus on advancing our pioneering cancer vaccine technology further in the clinic and establishing key partnerships," said Bill Watt, Ph.D., Founder, President and Chief Executive Officer of EpiThany. "We are thrilled to have David join us as we work to become the first company to develop Th1-selective, multi-antigen vaccines for patients with solid tumors."

Prior to the Allen Institute, Poston served as Vice President, Chief Financial Officer, Secretary and Treasurer for AmpliPhi Biosciences Corporation (formerly Targeted Genetics Corporation). Poston has previously held a series of finance and leadership positions at Corixa Corporation (now GSK), Honeywell Marine Systems (now Raytheon), Todd Shipyards Corporation (now Vigor Industrial), and Olin/Rocket Research Company (now Aerojet Rocketdyne). He received his B.A. in business administration from the University of Puget Sound, where he serves as a Business Leadership mentor and recently served as Chair of its Alumni Fund and member of its Alumni Council Executive Committee. He also serves on the Boards of Life Science Washington and Plymouth Housing Group.

"EpiThany is at an exciting stage in its development as it works to advance the promising science developed at the Tumor Vaccine Group, and I am very pleased to join this high caliber team," said Poston.

About EpiThany

EpiThany, Inc. is dedicated to the advancement of innovative therapies to improve the lives of cancer patients.  EpiThany's groundbreaking technology enables the targeting of a multitude of tumor antigens across a spectrum of cancers, driving Th1-selective (tumor-eradicating) immune responses. EpiThany was launched in 2014 on the R&D platform developed at the Tumor Vaccine Group (TVG) at the University of Washington by pioneering cancer vaccine researcher Nora Disis, scientific co-founder of the company. For more information, visit

Media Contact:
Julie Rathbun
Rathbun Communications

For more information:

Editor's Details

Mike Wood

Last updated on: 23/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.